Background: Renal impairment (RI) is a most common complication of multiple myeloma (MM), which is associated with an increased risk of early death and worse survival.
Health Organization (WHO) defines "elderly" as older than the age of 65 years, the aging is a evidently heterogeneous phenomenon. 3 The incidence of MM increases steadily with advanced age. 4 Meanwhile, the incidence of various complications in elderly MM patients also is increased. As we all know, renal impairment (RI) is a most common complication of MM that can be present at diagnosis or emerge during therapy. 5, 6 RI can be elicited by various factors, such as infections, non-steroidal anti-inflammatory drugs, nephrotoxic antibiotics, iodinated contrast media, hypercalcemia, tumor lysis syndrome, myeloma cell infiltration of the kidney, and renal vein or artery thrombosis, and, frequently, by clonotypic light chains. 7 The presence of RI places the patients at higher risk for complications after anti-myeloma treatment and is associated with an increased risk of early death. 8 The MM patients with advanced age are usually excluded from clinical trials due to poor performance status (PS), various complications, and socioeconomic reasons. 9 Therefore, limited scientific data are available regarding the clinical characteristics and treatment outcomes in this group of patients. 10, 11 
| PATIENTS AND ME THODS
A total of 77 consecutive patients with newly diagnosed MM from
October 2010 to December 2015 were retrospectively analyzed.
Twenty patients refused chemotherapy and only received supportive treatment. Treatment responses were evaluated according to the international uniform response criteria for multiple myeloma. 12 The reduction or suspension of treatment was determined according to the decision of the physician, the patient, or their family. Multiple baseline characteristics of the patients were collected from the medical records (Tables 1 and 2 ). Response to treatment was assessed by the International Myeloma Working Group (IMWG) criteria. 12, 13 Renal function and renal response to therapy were assessed. Renal Clinical baseline characteristics of two groups were described as mean ± SD for normal distributed continuous variables and median for non-normally distributed variables. Categorical variables were described as percentages. Table 1 shows the clinical and laboratory characteristics between the patients with or without RI. The percentages of patients without RI and with RI were 39% and 61%, respectively. There were significant differences in hypertension, ISS stage, hemoglobin, BUN, creatinine, GFR, LDH, and β2-microglobulin between the two groups, while no differences in age, sex, diabetes, light chain isotype, IgA isotype, leukocyte, thrombocyte, globulin, albumin, alkaline phosphatase, calcium, or myeloma cell. Hemoglobin levels were protective factors (OR = 0.954, P = 0.033), while creatinine and hypertension were hazards (OR = 1.288, P < 0.001 and OR = 30.12, P = 0.008). Table 2 shows the clinical and laboratory characteristics between the patients with mild-to-moderate RI and moderate-to-severe RI, which were 40.4% and 59.6%, respectively. There were significant differences in diabetes, BUN, creatinine, GFR, and β2-microglobulin between the two groups.
| RE SULTS

| Baseline characteristics
| Treatment outcome
Fifty-seven patients received chemotherapy, including TD, VAD, and MP (non-bortezomib group, n = 30) or VD, VCD, and VTD (bortezomib group, n = 27, 2 patients had no therapeutic evaluation). Table 3 shows the treatment outcomes of the two groups. CR rate was higher in bortezomib group (non-bortezomib and bortezomib;
3.33% and 33.3%, respectively, P = 0.007). Furthermore, there were 21 patients whose GFR is <50mL/min received chemotherapy. We found that CRrenal was higher in bortezomib group (non-bortezomib and bortezomib; 22.2% and 58.3%, respectively, P = 0.025) ( Table 4 ). of the group with mild-to-moderate RI and moderate-to-severe RI was 10.0 and 9.0 months, and the median OS of these two groups was 12.0 and 9.0 months. Log-rank analysis indicated that there was no significant difference in PFS and OS between these two groups, while we found PFS and OS of the group with mild-to-moderate RI were longer than those with moderate-to-severe RI. Furthermore, the median OS of the group with RI and with moderate-to-severe RI treating with the bortezomib-containing regimens was longer than those with non-bortezomib-containing regimens, 15.0 vs 6.0 months and 13.0 vs 6.0 months, respectively, P = 0.001 and P = 0.007) ( Figure 2) . 19 Bortezomib has excellent activity in MM at any stage of the disease and is synergistic with other drugs, which led to several combination strategies. VMP was proven superior to MP in response rate, CR rate, median TTP (time to progression), and OS, even over all cytogenetic and renal failure subgroups. 20 The improvement in RI to a near-normal range (CrCL ≥60 mL/min) observed in the majority of MM patients in the current study suggests that bortezomib may be a particularly useful therapy in this setting. In our study, CR rate was higher in patients treated with bortezomib. As the similar result, CRrenal was higher in bortezomib group. Among the patients ≥70 years old, patients without RI showed significantly longer PFS and OS compared to those with RI.
| Progression-free and overall survival
The OS of patients during the treatment of bortezomib-containing regimens in mild-to-moderate RI and moderate-to-severe RI group was longer than those without RI.
In conclusion, we showed that elderly MM patients with RI, using first line of bortezomib-containing regimens treatment, can achieve higher CR and CRrenal rates, and prolong their survival. 
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